This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the potential of Takeda's Dengue Vaccine candidate, QDENGA, and Valneva SE's single-shot Chikungunya Vaccine candidate, VLA1553

Ticker(s): TAK, VALN

Who's the expert?

Institution: Weill Cornell Medicine

  • Associate Professor of Medicine at Weill Cornell & Associate Attending Physician at New York- Presbyterian Hospital.
  • Research focused on influenza virus pathogenesis and therapy in the immunocompromised human host.
  • Member of the International Society for Travel Medicine (ISTM) and she a fellow of the Infectious Diseases Society of America (IDSA).

    Interview Questions

    Can you please discuss your background in specialty infectious diseases and  travel medicine?

    Added By: sara_admin

    How optimistic are you about the efficacy and approval of Takeda's Dengue Vaccine candidate, QDENGA(TAK-003)?

    Added By: sara_admin

    How optimistic are you about Valneva SE's single-shot Chikungunya Vaccine candidate, VLA1553, based on the data from the Phase 3 VLA1553-301 trial of VLA1553 in adults?

    Added By: sara_admin

    Are You Interested In These Questions?

    Slingshot Insights Explained

    Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


    *Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.